Same Drug Class

Nivolumab vs Osimertinib

Nivolumab vs Osimertinib: Overview

This comparison examines the pharmacological differences between Nivolumab and Osimertinib.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Osimertinib — 48 hours.

Chemical Properties

Molecular Formula: Osimertinib — C28H33N7O2.

Molecular Weight: Osimertinib — 499.6050 g/mol.

Type: Nivolumab — Antibody; Osimertinib — Small molecule.